JRHIF yields 4.84% · JNJ yields 2.13%● Live data
📍 JRHIF pulled ahead of the other in Year 1
Combined, JRHIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JRHIF + JNJ for your $10,000?
Daiwa Securities Living Investment Corporation (hereinafter referred to as "the Investment Corporation") is listed on the Tokyo Stock Exchange in June 2006 (stock code: 8986) and is located in the metropolitan area and major cities throughout Japan (Sapporo City, Sendai City) It is a rental apartment specialized REIT (REIT) that invests in rental apartments in Nagoya City, Osaka City, Fukuoka City, etc. After the acquisition of Prospect Reit Investment Corporation in July 2010, the Investment Corporation will actively replace properties (acquisition of new properties) with the management ability of the asset management company Daiwa Real Estate Asset Management Co., Ltd. And the sale of existing properties), drastic operation reinforcement (achievement of high occupancy rate), various cost reductions, etc., and we have achieved improvement in distribution. In December 2015, Daiwa Securities Group Inc. (hereinafter referred to as "Daiwa Securities Group Inc.") will acquire additional shares of the asset management company, and the Investment Corporation will bring Daiwa Securities Group Inc. as a new sponsor have become. The Investment Corporation will use its support based on the sponsor-support agreement concluded between the asset management company and the Daiwa Securities Group headquarters to aim for sustainable and stable growth. The Investment Corporation will continue to aim to maximize the profits of its investors. We would like to ask all investors for their continued support and rewards.
Full JRHIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.